InterVenn
South San Francisco
About InterVenn
InterVenn is a life science company unlocking the value of glycoproteomics’glycosylated proteins which are responsible for driving protein function’for the development of transformational healthcare solutions. The glycoproteome is a source of life-critical information about human biology that has the potential to improve patient outcomes significantly. Still, it has remained inaccessible due to its vast complexity. InterVenn has pioneered a first-of-its-kind AI-powered platform to decode this layer of biology at a clinically meaningful scale for the first time in history. The company’s platform can produce a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and, potentially, therapeutics. Its proprietary technology platform is accessible to pharma partners seeking rich biology insights to propel their research and development efforts. Founded by Nobel Laureate Dr. Carolyn Bertozzi, world-class scientist and distinguished professor Dr. Carlito Lebrilla and leading AI/ML expert & serial entrepreneur Aldo Carrascoso, InterVenn will contribute to making the new era of personalized, predictive, and preventative care a reality. For more information about InterVenn, visit www.intervenn.com.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $244.4M
- Funding stage: Late Stage Venture
- Last round: Series C (Aug 2021)
- Website: intervenn.com
- Phone: 888-706-1670
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Health Care, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/intervenn-118275 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.